Elements DNA
Published research · Hormone

PT-141 Nasal Spray

Bremelanotide

Cyclic heptapeptide studied as a melanocortin receptor agonist

5 papers · 2004–2025 · 3 journals

What the research explores

Melanocortin receptor pharmacology is the research context for this compound. The receptor family spans five subtypes with distinct tissue distributions, and published work explores:

  • Agonist potency and subtype selectivity across MC1R, MC3R and MC4R
  • cAMP signalling profiles in receptor-transfected cell lines
  • How backbone cyclisation alters conformational rigidity and receptor engagement
  • Central versus peripheral melanocortin signalling in preclinical animal models
  • Solution stability and analytical characterisation of the peptide in aqueous formulation

These are areas of published scientific investigation. Elements DNA makes no representation about any physiological effect in humans and supplies this material for laboratory research use only.

References

A reference list, not evidence. Inclusion means a paper discusses the compound — not that it supports any use, and not that it describes this product.

  1. 2025

    1. A biodegradable suction patch for sustainable transbuccal peptide delivery

      Krupke H, Zoratto N, Rabut L, et al.

      Journal of controlled release : official journal of the Controlled Release Society

      PMID 40513668doi 10.1016/j.jconrel.2025.113947

  2. 2019

    1. Bremelanotide: First Approval

      Dhillon S, Keam SJ

      Drugs

      PMID 31429064doi 10.1007/s40265-019-01187-w

  3. 2012

    1. Bremelanotide

      PMID 34436837

  4. 2006

    1. Bremelanotide

      PMID 31369224

  5. 2004

    1. PT-141 Palatin

      Hedlund P

      Current opinion in investigational drugs (London, England : 2000)

      PMID 15134289

More research in hormone

For laboratory and research use only · Not for human or veterinary consumption · Not evaluated by the FDA